1. Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation.
- Author
-
Schewel D, Frerker C, Schewel J, Wohlmuth P, Meincke F, Thielsen T, Kreidel F, Kuck KH, and Schäfer U
- Subjects
- Aged, Aged, 80 and over, Aortic Valve Insufficiency blood, Aortic Valve Insufficiency diagnosis, Aortic Valve Insufficiency mortality, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Biomarkers blood, Cardiac Catheterization adverse effects, Cardiac Catheterization mortality, Female, Germany, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Predictive Value of Tests, Proportional Hazards Models, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Aortic Valve Insufficiency etiology, Aortic Valve Stenosis therapy, Cardiac Catheterization instrumentation, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Prosthesis Failure
- Abstract
Background: There is accumulating evidence that up to 20% of the implanted devices after TAVI are associated with a significant degree of paravalvular leaks, which appear to be associated with a negative clinical outcome., Methods: A total of 355 patients with severe aortic valvular stenosis (AVS) were treated by TAVI (Corevalve n = 222, Edwards Sapien n = 133). Survival, NT-proBNP and the grade of PVL were quantified up to 12 months after implantation., Results: Technical success rate was 97.8%. Thirty-day mortality was 9.6%. Post-procedural transvalvular aortic regurgitation was seen only in a minority of cases (5%), whereas PVL were frequently observed (grade: <1+ in 58.2%, ≥1-<2 in 33.9%, and ≥2 in 7.9%). There was a clear relation-ship between PVL and adverse outcome (P < 0.001). After a transient increase, NT-proBNP showed a significant decline. Interestingly, a PVL ≥2+ was associated with a much higher rise in NT-proBNP compared to the other groups (P < 0.01), and a post-procedural increase in NT-proBNP by more than 1640 ng L(-1) within 5 days was associated with a significant increase in rate of death (P < 0.01)., Conclusions: TAVI is an efficient treatment option for high-risk patients with severe AVS. The incidence of PVL is an inacceptable clinical problem. Serial measurement of NT-proBNP can be used for risk-stratification in patients with a significant PVL. In general, PVL graded ≥2+ is associated with a dramatically increased 6-month mortality. Therefore, any action to reduce paraprosthetical regurgitation is highly recommended., (© 2013 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF